Madrigal Pharma (MDGL) Doses First Patient in MGL-3196 Phase 2 as NASH Treatment
Tweet Send to a Friend
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced that the first patient has been dosed in its Phase 2 study of MGL-3196 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
